Pharmacological Modulation of the STING Pathway for Cancer Immunotherapy

The host STING pathway has been identified as a crucial mechanism of innate sensing of cancer and tumor growth. Activation of the cGAS-STING-IRF-3 cascade leads to the priming and infiltration of CD8+ T cells through type I IFN production and triggers potent antitumor immunity. The STING protein is now well characterized and ligand-bound crystal structures are available, allowing for the design of novel agonists. In vitro and in vivo data using CDN and non-CDN STING agonists suggest a robust and sustained antitumor effect. Accumulating in vitro and in vivo evidence shows the potential of STING agonists as promising immunotherapies for cancer patients, which will be applied in the near future. The advent of immunotherapy in recent years has shown the potential to revolutionize the treatment of cancer. Unleashing antitumor T cell responses via immune checkpoint blockade has led to remarkable responses in previously untreatable tumors. The master regulator of interferon-mediated antiviral responses – stimulator of interferon genes (STING) – has now emerged as a critical mediator of innate immune sensing of cancer, and is a promising target for local immunostimulation, promoting intratumoral inflammation, and facilitating antitumor T cell responses. Pharmacological activation of the STING pathway can lead to T cell-mediated tumor regression in preclinical tumor models, and novel STING activating small molecules are now being tested in clinical trials. Here we will introduce the STING pathway and review the current state of drug development. The advent of immunotherapy in recent years has shown the potential to revolutionize the treatment of cancer. Unleashing antitumor T cell responses via immune checkpoint blockade has led to remarkable responses in previously untreatable tumors. The master regulator of interferon-mediated antiviral responses – stimulator of interferon genes (STING) – has now emerged as a critical mediator of innate immune sensing of cancer, and is a promising target for local immunostimulation, promoting intratumoral inflammation, and facilitating antitumor T cell responses. Pharmacological activation of the STING pathway can lead to T cell-mediated tumor regression in preclinical tumor models, and novel STING activating small molecules are now being tested in clinical trials. Here we will introduce the STING pathway and review the current state of drug development. principally involving B and T lymphocytes, the adaptive immune system produces memory cells following interaction with antigens, leading to long-lasting and efficient responses. The primary response drives the production of antigen-specific antibodies by B lymphocytes and generates antigen-specific T cells. The secondary response following encounter with the same antigen is faster and reactivates memory cells that were first produced. include macrophages, dendritic cells (DCs), and B cells. Their role is to display antigens (via MHC class II binding) after pathogen engulfment and to promote immune response by recruiting T helper cells. these are cytotoxic T cells responsible for eliminating pathogen infected cells and damaged cells. T cells directly bind to antigens presented by MHC class I on the cell surface. potent APCs that link the innate immune system to its adaptive arms by inducing activation and differentiation of naïve T cells, by expression and presentation of the antigen on MHC class II, priming immature CD4+ and CD8+ T cells. key regulatory elements which normally function to limit the immune response. Hijacked by cancer cells to avoid T cell-mediated killing. the innate immune defense consists of external barriers (such as the skin and mucosal membranes), various white blood cells and soluble proteins, which act rapidly and nonspecifically against the entry and spread of pathogens in the body. these are secreted proteins and a subclass of cytokines produced by host cells in response to pathogens (bacteria, viruses, microorganisms, parasites) or tumor cells. Their role is to mediate crosstalk between different immune system components and activate macrophages, natural killer cells, and APCs. these are a type of antigen-specific T lymphocytes whose role is to suppress or downregulate induction and proliferation of effector T cells. these are lymphocytes which migrate from the blood circulation into the tumor microenvironment. comprises the environment surrounding the tumor. It includes: extracellular matrix, signaling proteins, immune cells, blood vessels, and fibroblasts.